Lawsuits, Just the Cost of Criminal Marketing of Antipsychotic Drugs
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.”
"When you’re selling $1 billion a year or more of a drug, it’s very tempting for a company to just ignore the traffic ticket and keep speeding.”
"What’s gone on with the pharmaceutical industry is a physician arms race to buy off doctors…"
The prescribed drugs transformed Kyle Warren from a rambunctious healthy child into a drooling, sedated, obese, “shell.”
A stunning admission of failure by major drug manufacturers who market drugs for the treatment of Alzheimer’s. "We really believe drugs are failing because we honestly don’t understand the disease."
Despite the fact that children may be at highest risk of antidepressant-induced suicide, GlaxoSmithKline is testing Paxil on 7 to 18 year old Japanese children.
"The resulting frenzy of psychiatric diagnoses has damaged the credibility of everyone in the field."
A large-scale Harvard meta-analysis published in the Journal of the American Medical Association, is the first ever to evaluate the relationship between different anticonvulsant drugs and the risk of suicide in for patients with diverse diagnoses: " the risk was derived from the specific drug that the patient was taking and not their underlying conditions."
An educator with an insightful sense of humor calls psychiatry’s proclivity to designate all manner of human behavior as pathological–an affront.
"500 people would need to be treated with Crestor for a year to avoid one usually survivable heart attack. Stroke numbers were similar…At $3.50 a pill, the cost of prescribing Crestor to 500 people for a year would be $638,000 to prevent one heart attack."
"For her last month of life, Kifuji overall prescribed 835 pills to Rebecca….If what Dr. Kifuji did in this case is the acceptable standard of care for children in Massachusetts, then there is something very wrong in this state."
"Her mother’s murder trial has been over for a couple of weeks now, but I’m still haunted by little Rebecca Riley."
"Does this appointment signify that Harvard Medical School intends to even further strengthen its research ties to the pharmaceutical industry?"